Aptose appoints Philippe Ledru as CCO; CFO Jotin Marango resigns

Aptose Biosciences Inc.

Philippe Ledru appointed CCO effective April 6, 2022; base salary $410K with up to 40% bonus.
Dr. Jotin Marango resigns as CFO/CBO to pursue other opportunity; CEO Dr. Rice assumes CAO role.
Ledru receives a stock option grant for 600,000 common shares under Aptose's 2021 Stock Incentive Plan.
Ledru previously held senior commercial roles at Merck and Novartis, including oncology pipeline leadership.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Philippe Ledru

Chief Commercial Officer

APTOF · Aptose Biosciences Inc.

Effective: 2022-04-06
Filed: April 11, 2022, 7:59 PM ET

On April 6, 2022, Aptose Biosciences Inc. appointed Mr. Philippe Ledru as its Chief Commercial Officer.

Departed

Jotin Marango

Senior Vice President, Chief Financial Officer and Chief Business Officer

APTOF · Aptose Biosciences Inc.

Filed: April 11, 2022, 7:59 PM ET

Aptose also announced on April 07, 2022 that Dr. Jotin Marango, Senior Vice President, Chief Financial Officer and Chief Business Officer, is resigning to pursue another opportunity.

Role change (interim)

Dr. Rice

Chief Accounting Officer

APTOF · Aptose Biosciences Inc.

Filed: April 11, 2022, 7:59 PM ET

Dr. Rice will serve as Chief Accounting Officer, and with Ms. Janet Clennett, Vice President of Finance, will assume financial responsibilities until a permanent CFO is announced.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Philippe Ledru was appointed as Chief Commercial Officer at Aptose Biosciences Inc..

Action: appointed
Role: Chief Commercial Officer

Exact text from the filing

On April 6, 2022, Aptose Biosciences Inc. appointed Mr. Philippe Ledru as its Chief Commercial Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jotin Marango departed as Senior Vice President, Chief Financial Officer and Chief Business Officer at Aptose Biosciences Inc..

Action: resigning
Role: Senior Vice President, Chief Financial Officer and Chief Business Officer

Exact text from the filing

Aptose also announced on April 07, 2022 that Dr. Jotin Marango, Senior Vice President, Chief Financial Officer and Chief Business Officer, is resigning to pursue another opportunity.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Dr. Rice changed role as Chief Accounting Officer at Aptose Biosciences Inc..

Action: will serve as
Role: Chief Accounting Officer

Exact text from the filing

Dr. Rice will serve as Chief Accounting Officer, and with Ms. Janet Clennett, Vice President of Finance, will assume financial responsibilities until a permanent CFO is announced.

View on SEC.gov

Aptose Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001171843-22-002529

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.